TGFB1 and neoplasm: Therefore, immunotherapies targeting TGF-β activation or signaling may inhibit the tumor-promoting effects of EPCs and the tumor-promoting effects of TGF-β, thereby improving the efficacy of immunotherapies for various cancers.